8-K: Edwards Lifesciences Exceeds Q3 Expectations, Raises 2025 Outlook

Edwards Lifesciences reported strong third-quarter 2025 financial results, driven by double-digit sales growth across all product groups, leading to increased full-year guidance.

Summary

• Third-quarter 2025 sales grew 14.7% to $1.55 billion, or 12.6% on an adjusted basis, with broad strength across all product groups.
• Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.15 billion, growing 12.4% (10.6% constant currency).
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were $145.2 million, demonstrating significant growth of 59.3% (53.2% adjusted), primarily driven by PASCAL and EVOQUE systems.
• Surgical Structural Heart sales increased 7.5% to $258 million (5.6% constant currency).
• Reported diluted Earnings Per Share (EPS) for Q3 2025 was $0.50, while adjusted EPS was $0.67.
• Full-year 2025 sales growth guidance has been increased to the high end of 9-10%.
• Full-year 2025 TAVR sales growth guidance has been raised to 7-8% from 6-7%.
• Full-year 2025 adjusted EPS guidance has been increased to a range of $2.56 to $2.62, up from the high end of $2.45 to $2.55.
• The company projects total sales for the fourth quarter to be between $1.51 billion and $1.59 billion, with adjusted EPS of $0.58 to $0.64.
• Cash and cash equivalents totaled approximately $3 billion as of September 30, 2025, with total debt around $600 million.
• The Board of Directors approved an increase in the share repurchase authorization, now totaling approximately $2.1 billion.

Sentiment

Score: 9

Explanation: The company reported strong double-digit sales growth across all product lines, significantly raised its full-year sales and EPS guidance, and highlighted positive clinical trial data and favorable guideline updates. This indicates robust operational performance, strong market position, and positive future prospects, despite some non-GAAP adjustments and increased expenses.

Positives

• Double-digit sales growth of 14.7% (12.6% adjusted) in Q3 2025, indicating strong market demand and product adoption.
• Significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales by 59.3% (53.2% adjusted), highlighting successful expansion in these therapeutic areas.
• Raised full-year 2025 sales growth guidance to the high end of 9-10% and TAVR sales guidance to 7-8%, reflecting confidence in continued performance.
• Increased full-year 2025 adjusted EPS guidance to $2.56-$2.62, signaling improved profitability expectations.
• Positive clinical trial outcomes, including SAPIEN 3 demonstrating long-term outcomes equivalent to surgery at 7 years and supported by 10-year PARTNER 2 follow-up.
• EVOQUE real-world data from over 1,000 patients showed impressive safety and efficacy results for tricuspid valve therapy.
• SAPIEN M3 achieved its primary endpoint in the pivotal ENCIRCLE trial for mitral replacement, indicating a promising new therapy.
• New ESC/EACTS guidelines simplify care pathways for severe AS patients, potentially expanding the treatable patient population.
• Strong adjusted operating profit margin of 27.5% in Q3, benefiting from better-than-expected sales performance.
• Increased share repurchase authorization by approximately $2.1 billion, demonstrating commitment to shareholder returns.

Negatives

• GAAP diluted EPS for Q3 2025 was $0.50, lower than the adjusted EPS of $0.67, indicating significant non-GAAP adjustments.
• Adjusted gross profit margin decreased to 77.9% in Q3 2025 from 80.7% in Q3 2024, primarily due to foreign exchange impacts.
• Selling, general and administrative (SG&A) expenses increased to 33.1% of sales in Q3 2025 from 31.1% in Q3 2024, reflecting higher investment to support global growth.
• Reported operating income decreased to $307.1 million in Q3 2025 from $350.6 million in Q3 2024.
• Higher certain litigation expenses of $90.4 million in Q3 2025 compared to $10.8 million in Q3 2024.
• Recorded a $40.0 million intangible assets impairment charge in Q3 2025 related to developed technology from an acquisition.

Risks

• Forward-looking statements are inherently uncertain, difficult to predict, and may be outside of the company's control.
• Any modification to existing tariffs or new tariffs could have a material impact on future financial results and guidance.
• Risks and uncertainties detailed in the company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, could cause actual results to differ materially.

Future Outlook

Edwards Lifesciences is increasing its full-year 2025 total company sales growth guidance to the high end of 9% to 10% and raising TAVR sales growth guidance to 7% to 8%. Adjusted EPS guidance for the full year is now expected to be between $2.56 and $2.62. The company remains committed to being a partner of choice for heart teams, focusing on structural heart, including extending into heart failure and aortic regurgitation, which represents a significant opportunity for differentiated long-term value.

Management Comments

• Bernard Zovighian, CEO, stated, 'Our strong results represent another quarter of double-digit sales growth, driven by our comprehensive portfolio across multiple therapeutic areas – aortic, pulmonic, mitral and tricuspid – and our established presence in countries around the world.'
• Zovighian added, 'Based on our better-than-expected performance, reflecting the patient-focused contributions of our talented employees, we are raising our 2025 sales and EPS guidance.'
• Zovighian emphasized, 'Edwards remains committed to being the partner of choice for heart teams by providing a complete portfolio of therapies for the many patients in need, built on the foundation of our unique strategy and an unprecedented body of evidence.'
• Zovighian highlighted, 'Our focus on structural heart, including extending into heart failure and aortic regurgitation, represents a tremendous opportunity with the potential to drive differentiated long-term value.'

Industry Context

The announcement reflects a robust market for transcatheter heart therapies, with Edwards Lifesciences benefiting from new clinical evidence and updated guidelines. The new ESC/EACTS guidelines for valvular heart disease, which simplify care pathways for severe AS patients regardless of symptoms, are a meaningful step forward, enabling a proactive approach to disease management. A competitor's exit in Europe also contributed modestly to Edwards' TAVR sales, indicating market rebalancing. The company's strong performance in TMTT, driven by PASCAL and EVOQUE, aligns with a growing trend towards less invasive treatment options for mitral and tricuspid diseases.

Comparison to Industry Standards

• The 7-year data for the PARTNER 3 pivotal trial, confirming SAPIEN 3's all-cause mortality rates and valve performance comparable to surgical aortic valve replacement (SAVR) for low-risk patients, sets a new global benchmark for TAVR durability.
• The SAPIEN platform, with over 15 years of clinical trials, 10,000+ patients, and 1.2 million patients treated globally, demonstrates a leading position in the TAVR market, offering both early clinical benefits and proven long-term durability.
• The EVOQUE real-world data, with over 1,000 patients, showed continued high levels of tricuspid regurgitation elimination and strong safety outcomes, surpassing pre-market randomized trial results and establishing a strong efficacy profile in a challenging patient population.
• The ENCIRCLE study for SAPIEN M3, as the first-ever pivotal trial for any transfemoral mitral replacement therapy, demonstrates meaningful early benefits in mortality reduction and quality of life improvement, positioning it as a potential leader in a nascent but high-need market.

Corporate Governance

Legal Proceedings

• The company incurred certain litigation expenses of $90.4 million in the third quarter of 2025, compared to $10.8 million in the same period last year.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and increased share repurchase authorization, potentially leading to higher stock valuation.
• Patients: Significant positive impact through the continued development and adoption of innovative transcatheter therapies (TAVR, TMTT) and surgical solutions, supported by compelling clinical evidence and simplified care guidelines.
• Employees: Positive impact from the company's strong performance and growth, as acknowledged by the CEO's comments on 'patient-focused contributions of our talented employees'.
• Healthcare Providers/Clinicians: Enhanced treatment options and simplified care pathways for patients with structural heart diseases, supported by robust clinical data and guideline updates, strengthening Edwards' position as a partner of choice.
• Competitors: The exit of a competitor in Europe led to a rebalancing of the market, modestly contributing to Edwards' sales, indicating a potential shift in market share.

Next Steps

• Continue to generate evidence on the RESILIA portfolio and expand global access.
• Focus on structural heart, including extending into heart failure and aortic regurgitation.
• Host a conference call on October 30, 2025, at 2:00 p.m. PT to discuss third-quarter results.

Key Dates

Recommendation

Edwards Lifesciences delivered exceptional Q3 2025 results, significantly surpassing expectations with double-digit sales growth across all key segments. The company's decision to raise its full-year sales and adjusted EPS guidance underscores strong operational momentum and confidence in its market leadership. Breakthrough clinical data for SAPIEN 3, EVOQUE, and SAPIEN M3, coupled with favorable new ESC/EACTS guidelines, solidify its competitive advantage and expand its addressable market. The increased share repurchase authorization further signals management's commitment to shareholder value. Despite some non-GAAP adjustments and increased SG&A, the core business performance and future outlook are robust, making it a compelling 'strong buy' for long-term investors.

Keywords

Edwards Lifesciences, EW, Q3 2025 Earnings, Financial Results, TAVR, Transcatheter Aortic Valve Replacement, TMTT, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, SAPIEN 3, EVOQUE, SAPIEN M3, Medical Devices, Structural Heart Disease, Aortic Stenosis, Mitral Regurgitation, Tricuspid Regurgitation, Clinical Trials, Guidance Update, SEC Filing